Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PFE stock price vs ABT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ABT's multiple
Needs ABT P/E.
Implied fair value · at PFE's multiple
Needs PFE P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PFIZER INC · implied price per share
Bear
$10.17
Base
$12.82
Bull
$17.53
ABBOTT LABORATORIES · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
JOHNSON & JOHNSON
PFE vs JNJ
Merck & Co., Inc.
PFE vs MRK
AbbVie Inc.
PFE vs ABBV
BRISTOL MYERS SQUIBB CO
PFE vs BMY
ELI LILLY & Co
PFE vs LLY
AMGEN INC
PFE vs AMGN
Medtronic plc
PFE vs MDT
BECTON DICKINSON & CO
PFE vs BDX
Thermo Fisher Scientific Inc.
PFE vs TMO
DANAHER CORP /DE/
PFE vs DHR
BOSTON SCIENTIFIC CORP
PFE vs BSX
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PFE can reaccelerate growth while maintaining its current margin profile, then PFE may be attractive because it trades below ABT on every listed valuation multiple and below ABT-implied range; if not, the discount likely reflects its weaker growth and higher leverage.
PFE trades at a meaningful discount to ABT across P/E, P/S, EV/EBITDA, and EV/Revenue, with the stock price of $24.33 sitting below ABT-implied value range of $29.81 to $41.17. However, the discount is partly offset by PFE's softer growth and balance-sheet profile, so the valuation gap is not a straightforward bargain signal.
Supporting Metrics
